KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Revenue (2016 - 2025)

Historic Revenue for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $354.3 million.

  • Halozyme Therapeutics' Revenue rose 2212.46% to $354.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 3119.18%. This contributed to the annual value of $1.0 billion for FY2024, which is 2243.84% up from last year.
  • Halozyme Therapeutics' Revenue amounted to $354.3 million in Q3 2025, which was up 2212.46% from $325.7 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Revenue registered a high of $354.3 million during Q3 2025, and its lowest value of $89.0 million during Q1 2021.
  • Moreover, its 5-year median value for Revenue was $209.0 million (2022), whereas its average is $204.9 million.
  • The largest annual percentage gain for Halozyme Therapeutics' Revenue in the last 5 years was 25111.62% (2021), contrasted with its biggest fall of 1618.69% (2021).
  • Halozyme Therapeutics' Revenue (Quarter) stood at $102.0 million in 2021, then soared by 77.93% to $181.5 million in 2022, then increased by 26.75% to $230.0 million in 2023, then increased by 29.55% to $298.0 million in 2024, then rose by 18.88% to $354.3 million in 2025.
  • Its Revenue was $354.3 million in Q3 2025, compared to $325.7 million in Q2 2025 and $264.9 million in Q1 2025.